Archive for May, 2011


May 26th, 2011

Surprise! It’s Generic Combivir!

After last week’s unveiling of the new NNRTI rilpivirine, now we have a different kind of drug approval from the FDA: FDA granted approval for a generic formulation fixed dose combination of lamivudine and zidovudine tablets, 150 mg/300 mg, two nucleoside analogue reverse transcriptase inhibitors, indicated in combination with other antiretroviral agents for the treatment of […]

May 23rd, 2011

Rilpivirine Approved — the “iPod” of NNRTIs?

From the FDA on Friday (it’s always on Friday, isn’t it): FDA approved Edurant (rilpivirine) 25 mg tablets, a new non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV. Rilpivirine is an antiviral drug that helps to block reverse transcriptase, an enzyme necessary for HIV replication. The recommended dose of rilpivirine is one 25 mg […]

May 18th, 2011

HIV Exceptionalism and the Department of Unintended Consequences

Quick question:  If there were one piece of information — clinical or lab — that you would use to determine the quality of care in an HIV program, what would it be?  (Choose one.) Rates of influenza vaccine administration Receiving PCP prophylaxis with CD4 < 200 Adherence counseling before starting antiretroviral therapy Baseline toxoplasmosis serology Proportion of […]

May 17th, 2011

Physician Bloggers Categorized

About a year ago I linked this cartoon from “Dr. Fizzy”, and I’ve been a regular visitor to her site ever since. Anyway, more kudos to her for this dead-on categorization of MD bloggers. (I guess the British “spot-on” is a better choice for us docs.) Not exactly sure where I fit in this list — yikes — […]

May 12th, 2011

HPTN 052 Results — Another Win for Early HIV Therapy

The results of the HPTN Study 052 — which randomized 1,763 serodiscordant couples to early vs delayed ART to evaluate whether this reduced the risk of HIV transmission — have just been released: Findings from the study were reviewed by an independent Data and Safety Monitoring Board (DSMB) …The DSMB concluded that initiation of ART by HIV-infected […]

May 9th, 2011

Routine Screening for Anal Cancer: Are We There Yet?

A paper recently published in AIDS evaluated the cost effectiveness of various strategies for anal cancer screening in HIV positive men-who-have-sex-with-men (MSM). The “bottom line” (ahem): In HIV-infected MSM, the direct use of high resolution anoscopy is the most cost-effective strategy for detecting anal intraepithelial neoplasia Over on our Journal Watch AIDS Clinical Care site, Tim Wilkin from […]

May 4th, 2011

How Much Do ID/HIV Doctors Get Paid?

A long time ago, I was very close to becoming a Cardiologist.  Really. Even though my fascination with ID and microbiology started in medical school — and believe me, not much fascinated me in medical school — the fact that all the top residents in my program were going into Cardiology made me feel that somehow […]

HIV Information: Author Paul Sax, M.D.

Paul E. Sax, MD

Contributing Editor

NEJM Journal Watch
Infectious Diseases

Biography | Disclosures | Summaries

Learn more about HIV and ID Observations.